WallStreetZenWallStreetZen

NASDAQ: NRSN
Neurosense Therapeutics Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NRSN

Based on 1 analyst offering 12 month price targets for Neurosense Therapeutics Ltd

Min Forecast
$14.00+1,421.74%
Avg Forecast
$14.00+1,421.74%
Max Forecast
$14.00+1,421.74%

Should I buy or sell NRSN stock?

Based on 1 analyst offering ratings for Neurosense Therapeutics Ltd.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NRSN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates NRSN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NRSN stock forecasts and price targets.

NRSN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-22

1 of 1

Forecast return on equity

Is NRSN forecast to generate an efficient return?

Company
-14,747.22%
Industry
352.12%
Market
211.34%
NRSN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NRSN forecast to generate an efficient return on assets?

Company
4,545.02%
Industry
122.26%
NRSN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NRSN earnings per share forecast

What is NRSN's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.20
Avg 2 year Forecast
-$0.19
Avg 3 year Forecast
-$0.26

NRSN revenue forecast

What is NRSN's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.1M
Avg 2 year Forecast
$3.3M
Avg 3 year Forecast
$11.1M

NRSN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NRSN$0.92$14.00+1,421.74%Strong Buy
VTGN$0.56$0.90+60.71%Hold
INTS$0.37$2.25+514.75%Strong Buy
CLGN$1.89$11.50+508.47%Strong Buy
NEUP$4.02$21.00+422.39%Strong Buy
View Top Biotech Stocks

Neurosense Therapeutics Stock Forecast FAQ

Is Neurosense Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NRSN) stock is to Strong Buy NRSN stock.

Out of 1 analyst, 1 (100%) are recommending NRSN as a Strong Buy, 0 (0%) are recommending NRSN as a Buy, 0 (0%) are recommending NRSN as a Hold, 0 (0%) are recommending NRSN as a Sell, and 0 (0%) are recommending NRSN as a Strong Sell.

If you're new to stock investing, here's how to buy Neurosense Therapeutics stock.

What is NRSN's earnings growth forecast for 2026-2028?

(NASDAQ: NRSN) Neurosense Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Neurosense Therapeutics's earnings in 2026 is -$8,658,000.On average, 4 Wall Street analysts forecast NRSN's earnings for 2026 to be -$5,018,891, with the lowest NRSN earnings forecast at -$5,304,279, and the highest NRSN earnings forecast at -$4,649,855. On average, 4 Wall Street analysts forecast NRSN's earnings for 2027 to be -$4,767,946, with the lowest NRSN earnings forecast at -$4,580,968, and the highest NRSN earnings forecast at -$4,908,180.

In 2028, NRSN is forecast to generate -$6,273,613 in earnings, with the lowest earnings forecast at -$6,027,589 and the highest earnings forecast at -$6,458,131.

What is NRSN's revenue growth forecast for 2026-2028?

(NASDAQ: NRSN) Neurosense Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Neurosense Therapeutics's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast NRSN's revenue for 2026 to be $26,865,826, with the lowest NRSN revenue forecast at $0, and the highest NRSN revenue forecast at $55,330,809. On average, 4 Wall Street analysts forecast NRSN's revenue for 2027 to be $82,270,442, with the lowest NRSN revenue forecast at $0, and the highest NRSN revenue forecast at $169,362,956.

In 2028, NRSN is forecast to generate $272,889,876 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $497,214,605.

What is NRSN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NRSN) forecast ROA is 4,545.02%, which is higher than the forecast US Biotechnology industry average of 122.26%.

What is NRSN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NRSN price target, the average NRSN price target is $14.00, with the highest NRSN stock price forecast at $14.00 and the lowest NRSN stock price forecast at $14.00.

The Wall Street analyst predicted that Neurosense Therapeutics's share price could reach $14.00 by Dec 22, 2026. The average Neurosense Therapeutics stock price prediction forecasts a potential upside of 1,421.74% from the current NRSN share price of $0.92.

What is NRSN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NRSN) Neurosense Therapeutics's current Earnings Per Share (EPS) is -$0.36. On average, analysts forecast that NRSN's EPS will be -$0.20 for 2026, with the lowest EPS forecast at -$0.22, and the highest EPS forecast at -$0.19. On average, analysts forecast that NRSN's EPS will be -$0.19 for 2027, with the lowest EPS forecast at -$0.19, and the highest EPS forecast at -$0.20. In 2028, NRSN's EPS is forecast to hit -$0.26 (min: -$0.25, max: -$0.26).

What is NRSN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NRSN) forecast ROE is -14,747.22%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.